Sciclone Pharmaceuticals (SCLN) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	6-May-14
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'scln	'
Entity Registrant Name	'SCICLONE PHARMACEUTICALS INC	'
Entity Central Index Key	'0000880771	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	51,493,840

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$87,470	$85,803
Accounts receivable, net of allowance of $3,592 and $3,587 as of March 31, 2014 and December 31, 2013, respectively	32,271	40,008
Inventories	14,049	15,238
Restricted cash and investments	75	75
Prepaid expenses and other current assets	2,489	2,287
Deferred tax assets	107	'
Total current assets	136,461	143,411
Property and equipment, net	1,026	843
Deferred tax assets	'	374
Goodwill	34,435	35,357
Other assets	270	242
Total assets	172,192	180,227
Current liabilities:	'	'
Accounts payable	3,276	7,190
Accrued and other current liabilities	15,832	21,464
Deferred revenue	2,844	2,915
Deferred tax liabilities	'	368
Short-term borrowings on credit facilities	1,608	1,651
Total current liabilities	23,560	33,588
Deferred tax liabilities	101	'
Other long-term liabilities	76	44
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Preferred stock; $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding	'	'
Common stock; $0.001 par value; 100,000,000 shares authorized; 51,958,666 and 52,371,664 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	52	52
Additional paid-in capital	279,481	278,327
Accumulated other comprehensive income	3,317	4,176
Accumulated deficit	-134,395	-135,960
Total stockholders' equity	148,455	146,595
Total liabilities and stockholders' equity	$172,192	$180,227

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts	$3,592	$3,587
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	51,958,666	52,371,664
Common stock, shares outstanding	51,958,666	52,371,664

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Income (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Product sales, net	$26,064,000	$20,533,000
Promotion services	501,000	9,273,000
Total net revenues	26,565,000	29,806,000
Operating expenses:	'	'
Cost of product sales	4,561,000	4,618,000
Sales and marketing	9,834,000	11,199,000
Research and development	1,476,000	365,000
General and administrative	6,033,000	8,600,000
Total operating expenses	21,904,000	24,782,000
Income from operations	4,661,000	5,024,000
Non-operating income (expense):	'	'
Interest and investment income	19,000	19,000
Interest and investment expense	-29,000	-37,000
Other expense, net	-119,000	-16,000
Income before provision for income tax	4,532,000	4,990,000
Provision for income tax	398,000	787,000
Net income	$4,134,000	$4,203,000
Basic net income per share	$0.08	$0.08
Diluted net income per share	$0.08	$0.08

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Comprehensive Income (Loss) [Abstract]	'	'
Net income	$4,134	$4,203
Other comprehensive income (loss):	'	'
Net change in unrealized gain (loss) and foreign currency translation arising during the period on foreign currency denominated available-for-sale securities	'	-10
Foreign currency translation	-859	178
Total other comprehensive income (loss)	-859	168
Total comprehensive income	$3,275	$4,371

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net income	$4,134	$4,203
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Non-cash expense related to stock-based compensation	882	1,019
Depreciation and amortization	207	202
Loss on disposal of fixed assets	15	'
Other long-term liabilities	-29	-105
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	7,516	10,283
Inventories	1,188	2,766
Prepaid expenses and other assets	-288	-126
Accounts payable	-4,189	-5,503
Accrued and other current liabilities	-5,324	-1,808
Deferred revenue	5	'
Net cash provided by operating activities	4,117	10,931
Investing activities:	'	'
Purchases of property and equipment	-111	-41
Net cash used in investing activities	-111	-41
Financing activities:	'	'
Repurchase of common stock	-2,569	-2,500
Proceeds from borrowing on short-term loan	'	567
Proceeds from issuances of common stock	248	104
Net cash used in financing activities	-2,321	-1,829
Effect of exchange rate changes on cash and cash equivalents	-18	16
Net increase in cash and cash equivalents	1,667	9,077
Cash and cash equivalents, beginning of period	85,803	84,228
Cash and cash equivalents, end of period	$87,470	$93,305

Basis_Of_Presentation

Basis Of Presentation	3 Months Ended
	Mar. 31, 2014
Basis Of Presentation [Abstract]	'
Basis Of Presentation	'
	1.Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the audited consolidated financial statements and the notes thereto for the year ended December 31, 2013 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission (“SEC”). The Company prepared the unaudited condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other information that are normally required by GAAP can be condensed or omitted.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	The interim financial information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited condensed consolidated balance sheet data as of December 31, 2013 is derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ significantly from those estimates.
	Customer Concentration
	In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN®, the Company manufactures its product using its US and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Lingyun Biopharmaceutical (Shanghai) Co. Ltd. (“SinoPharm”). SinoPharm and its affiliates act as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for damaged product or quality control issues and after passage of title and risk of loss are transferred to SinoPharm at the time of shipment. After the Company’s sale, SinoPharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors.
	Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers.
	Customers that exceeded 10% of the Company’s total net revenue and related to the Company’s China segment were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Customer A		94%		66%
	Customer B		—		29%
	As of March 31, 2014, approximately $31.2 million, or 87%, of the Company's accounts receivable were attributable to two customers in China. The Company generally does not require collateral from its customers.
	Accounts Receivable
	Receivable Reserve. The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are charged off at the point when they are considered uncollectible. As of March 31, 2014, the Company had $7.6 million in accounts receivable that were past due ninety days or more. As of March 31, 2014 and December 31, 2013, the Company recorded a receivable reserve of approximately $3.5 million related to gross accounts receivable of $3.5 million from one customer that is more than one year past due. The accounts receivable reserve was established as a result of continual negotiations that indicate the accounts receivable balance may not be recoverable. The receivable reserve reflects the Company’s best estimate of the ultimate collection, though actual collections may vary and the Company continues to pursue the full amount of the accounts receivables. The Company also had an additional receivable reserve of $0.1 million as of March 31, 2014 and December 31, 2013 related to another customer due to the Company’s uncertainty of collecting a portion of the outstanding accounts receivable balance. The remaining amount past due ninety days or more related to receivables from affiliates of Sanofi Aventis S. A. (“Sanofi”) and had not been reserved for as of March 31, 2014 due to (i) the progress towards resolving the current dispute and (ii) the fact that a substantial portion of the total receivables due from Sanofi were offset by unrecognized revenue that had been deferred in the fourth quarter of 2013. Refer to further information regarding this matter under “Revenue Recognition” “Promotion Services Revenue.”
	Revenue Reserve. The Company maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which may result from expired or damaged product on delivery or for price reductions on the related sales and is based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired on delivery or are deemed to be damaged or defective when delivered. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of March 31, 2014 and December 31, 2013, the Company’s revenue reserves were immaterial.
	Revenue Recognition
	The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured.
	Product Revenue. The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to SinoPharm and its affiliates are recognized at time of shipment when title to the product is transferred to them. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors.
	Promotion Services Revenue. The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in the promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. In certain arrangements, the Company is required to return or refund a portion of promotion services fees received during interim periods from pharmaceutical customers if defined annual sales targets are not achieved. Under the Company’s agreements with these customers, if the agreement is terminated, and provided such targets have been met on a “pro rata” basis at the date of contract termination, the Company is entitled to retain the amounts paid. Due to the ability to retain amounts paid upon contract termination, provided applicable targets have been met on a “pro rata” basis at any interim date, the Company elected to recognize revenue during interim periods without reduction for amounts subject to refund based on Method 2 of Accounting Standards Codification 605-20-S99-1, “Accounting for Management Fees Based on a Formula.”
	The Company’s promotion agreements with Sanofi, consisting of individual promotional agreements for certain pharmaceutical products and supplementary agreements extending the terms thereof, were not renewed and expired on December 31, 2013. The Company received initial notification of non-renewal from Sanofi in early October 2013. Subsequent thereto, the Company believes that Sanofi breached its obligations under these agreements by, among other things, failing to supply product for the fourth quarter of 2013 in relation to sales the Company generated, and failing to pay promotion fees due to NovaMed Pharmaceuticals (Shanghai) Co. Ltd. (“NovaMed”) under the agreements. As of March 31, 2014 and December 31, 2013, the Company had $3.3 million and $4.3 million, respectively, of uncollected receivables due from Sanofi that related to revenue recognized during the first three quarters of 2013. The Company has demanded that Sanofi make full payment of the promotional fees due to NovaMed. If this matter is not resolved to the Company’s satisfaction, the Company intends to vigorously pursue its claims against Sanofi in arbitration. The Company is also pursuing settlement options outside of formal arbitration.
	The Company’s agreements with Sanofi contain provisions (identical regardless of individual product promotion agreement) that required a refund of a portion of promotion services fees received during interim periods from them if defined annual sales targets were not achieved. Consistent with the Company’s past practice, and consistent with its achievement (or excess achievement) of annual revenue targets in each prior period based on Method 2 of Accounting Standards Codification 605-20-S99-1, “Accounting for Management Fees Based on a Formula,” the Company recognized revenue during interim periods without reduction for amounts subject to refund because it met and substantially exceeded such targets on a “pro rata” basis at interim dates. The Company’s treatment of the subject-to-refund portion is consistent with the contractual provisions, which provide that the sales targets will be measured on a pro-rated basis if an agreement were to hypothetically terminate as of any given date.
	Due to Sanofi’s failure to place orders for shipment in the fourth quarter and fully meet the demand the Company generated, the Company’s actual promotional fees receivable in the fourth quarter of 2013 were negatively impacted. Due to this failure, the Company did not achieve the defined annual sales targets for fiscal 2013. Under the Company’s agreements with Sanofi, a failure to reach the annual sales target would result in approximately $6.2 million subject to refund related to the Company’s performance in the first three quarters of 2013. However, the Company’s agreements required that Sanofi continue to support the Company’s sales efforts by continuing to provide product through the end of the terms of the agreements. The Company believes it has no obligation to refund any amounts subject to this provision because its inability to achieve the defined annual sales was the result of a failure to perform by Sanofi.
	As the Company is in a dispute with Sanofi concerning Sanofi’s performance, the Company therefore deferred revenue recognition of approximately $2.8 million of Sanofi promotion fees related to the fourth quarter of 2013, pending resolution of the dispute. As the Company is legally entitled to at least the $2.8 million recorded as a receivable, the non-recognition of revenue resulted in an equal and offsetting amount of deferred revenue.
	Inventories
	Inventories consist of raw materials, work in progress and finished goods products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items, including pharmaceutical products approaching their expiry dates. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the impairment is first recognized. For the three-month period ended March 31, 2014, the Company did not record any write-downs related to inventory.
	Net Income Per Share
	Basic net income per share has been computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted net income per share is computed by dividing net income by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income per share includes any dilutive impact from outstanding stock options, restricted stock units (“RSUs”) and the employee stock purchase plan using the treasury stock method.
	The following is a reconciliation of the numerator and denominators of the basic and diluted net income per share computations (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2014			2013
	Numerator:
	Net income	$	4,134		$	4,203
	Denominator:
	Weighted-average shares outstanding used to
	compute basic net income per share		52,026			54,084
	Effect of dilutive securities		1,208			1,388
	Weighted-average shares outstanding used to
	compute diluted net income per share		53,234			55,472
	Basic net income per share	$	0.08		$	0.08
	Diluted net income per share	$	0.08		$	0.08
	For the three months ended March 31, 2014 and 2013, outstanding stock options and RSUs for 3,592,835 and 2,856,805 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options and RSUs calculated under the treasury stock method would have been anti-dilutive. In addition, for the three months ended March 31, 2014 and 2013, shares subject to market or performance conditions of 62,500 and 12,500, respectively, were excluded from the calculation of diluted net income per share because the performance or market criteria had not been met and the inclusion would provide an anti-dilutive effect.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	2.Fair Value Measurements
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. The three levels of input are:
	Level 1 - Quoted prices in active markets for identical assets or liabilities.
	Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and restricted cash and investments) measured at fair value on a recurring basis (in thousands):
		Fair Value Measurements as of March 31, 2014 Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for		Observable		Unobservable		Balance
			Identical Assets		Inputs		Inputs		as of
	Description		(Level 1)		(Level 2)		(Level 3)		31-Mar-14
	Certificate of deposit	$	—	$	75	$	—	$	75
	Money market funds		19,678		—		—		19,678
	Total	$	19,678	$	75	$	—	$	19,753
		Fair Value Measurements as of December 31, 2013 Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for		Observable		Unobservable		Balance
			Identical Assets		Inputs		Inputs		as of
	Description		(Level 1)		(Level 2)		(Level 3)		31-Dec-13
	Certificate of deposit	$	—	$	75	$	—	$	75
	Money market funds		28,262		—		—		28,262
	Total	$	28,262	$	75	$	—	$	28,337

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	3.Inventories
	Inventories consisted of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	7,763	$	7,746
	Work in progress		363		319
	Finished goods		5,923		7,173
		$	14,049	$	15,238
	Included in the Company’s inventory as of March 31, 2014 and December 31, 2013, was $1.6 million and $2.4 million, respectively, in inventory held at distributors related to products marketed by its NovaMed Pharmaceuticals, Inc. subsidiary.

Credit_Facilities

Credit Facilities	3 Months Ended
	Mar. 31, 2014
Credit Facilities [Abstract]	'
Credit Facilities	'
	4.Credit Facilities
	Credit Facility
	In December 2013, the Company’s subsidiary, NovaMed, entered into a 10.0 million Chinese Yuan Renminbi (“Renminbi”) revolving line of credit facility (approximately $1.6 million USD) and a maximum 15.0 million Renminbi loan facility (approximately $2.4 million USD) secured by its accounts receivable with Shanghai Pudong Development Bank Co. Ltd. (“the Credit Facility”). As of March 31, 2014, 10.0 million Renminbi (approximately $1.6 million USD) in borrowings were outstanding on the revolving line of credit facility that must be repaid by June 4, 2014 and early repayment is allowed. The Credit Facility bears interest on borrowed funds at the People’s Bank of China 6-month base rate plus 15% (6.44% as of March 31, 2014). The Credit Facility expires November 30, 2014 and any amounts borrowed must be repaid by the expiration date. For the three months ended March 31, 2014, the Company paid interest of approximately $26,000 related to the Credit Facility.
	Loan Agreement
	The Company’s previous loan agreement for 12.5 million Renminbi (approximately $2.0 million) with Shanghai Pudong Development Bank Co. Ltd. expired August 29, 2013. All amounts borrowed were repaid by the expiration date. The loan bore interest on borrowed funds at 7.5%.  For the three months ended March 31, 2013, the Company paid interest of approximately $31,000 related to this loan agreement.

Accrued_And_Other_Current_Liab

Accrued And Other Current Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued And Other Current Liabilities [Abstract]	'
Accrued And Other Current Liabilities	'
	5.Accrued and Other Current Liabilities
	Accrued and other current liabilities consisted of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Accrued taxes, tax reserves and interest	$	4,879	$	5,029
	Accrued sales and marketing expenses		4,210		6,419
	Accrued estimated SEC and DOJ investigation loss (Note 8)		2,000		2,000
	Accrued compensation and benefits		1,597		3,475
	Accrued professional fees		1,335		1,601
	Accrued manufacturing costs		915		1,617
	Other		896		1,323
		$	15,832	$	21,464

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	6.Accumulated Other Comprehensive Income (Loss)T
	Changes in the composition of accumulated other comprehensive income (loss) for the three months ended March 31, 2014 and 2013 are as follows (in thousands):
		Foreign
		Currency		Available-for-Sale
		Translation		Investments		Total
	Balances as of January 1, 2014	$	4,176	$	—	$	4,176
	Other comprehensive loss		-859		—		-859
	Balances as of March 31, 2014	$	3,317	$	—	$	3,317
		Foreign
		Currency		Available-for-Sale
		Translation		Investments		Total
	Balances as of January 1, 2013	$	3,055	$	-67	$	2,988
	Other comprehensive income (loss)		178		-10		168
	Balances as of March 31, 2013	$	3,233	$	-77	$	3,156

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	7.Stockholders’ Equity
	Stock-based Compensation
	The following table summarizes the stock-based compensation expenses included in the unaudited condensed consolidated statements of income (in thousands):
		Three Months Ended
		March 31,
			2014		2013
	Sales and marketing	$	201	$	246
	Research and development		47		9
	General and administrative		634		764
		$	882	$	1,019
	Stock Options
	During the three months ended March 31, 2014, the Company granted options to purchase a total of 1,434,500 shares of common stock and options to purchase 80,622 shares of common stock were exercised. As of March 31, 2014, there was approximately $5.7 million of unrecognized compensation expense, net of forfeitures, related to non-vested stock options, which is expected to be recognized over a weighted average remaining period of approximately 3.11 years.
	The Company has granted a total of 100,000 shares under two performance-based option awards to purchase shares of the Company’s common stock at an exercise price equal to the closing price of a share of the Company’s common stock as of the grant date. The options will fully vest upon meeting a performance goal within an established time frame. If the performance goal is met for the option within the established time frame, the option generally has a ten-year term measured from the date of grant. If the performance goal is not met within the established time frame, the option expires in its entirety. The grant date fair value per share of the performance-based awards has been calculated using the Black-Scholes option pricing model using the following assumptions: expected term of 4.95 to 5.97 years, volatility factor of 61.74% to 64.65%, and risk free interest rates of 0.95% to 1.49%. The Company recognizes expense related to a performance-based option over the period of time the Company determines that it is probable that the performance goal will be achieved. If it is subsequently determined that the performance goal is not probable of achievement, the expense related to the performance-based option is reversed. For the three-month periods ended March 31, 2014 and 2013, the Company recognized approximately $24,000 and $0, respectively, of expense related to performance-based options.
	RSUs
	During the three months ended March 31, 2014, 7,000 RSUs were granted and 625 RSUs vested and were released. As of March 31, 2014, there was approximately $0.6 million of unrecognized compensation cost, net of forfeitures, related to non-vested RSUs, which is expected to be recognized over a weighted average remaining period of approximately 1.17 years.
	Repurchase of Common Stock
	The Company’s Board of Directors has authorized a $50.5 million share repurchase program that expires December 31, 2014. The Company repurchased and retired 500,003 shares at a cost of $2.6 million during the three-month period ended March 31, 2014. As of March 31, 2014, $7.1 million of the $50.5 million share repurchase program authorized by the Board of Directors was available for future share repurchases. Repurchased shares have been retired and constitute authorized but unissued shares.

Contingencies_And_Commitments

Contingencies And Commitments	3 Months Ended
	Mar. 31, 2014
Contingencies And Commitments [Abstract]	'
Contingencies And Commitments	'
	8.Contingencies and Commitments
	Legal Matters
	The Company is a party to various legal proceedings and subject to government investigations, as noted in this section below. All legal proceedings and any government investigations are subject to inherent uncertainties, unfavorable rulings or other adverse events which could occur. Unfavorable outcomes could include substantial monetary damages or awards, injunctions or other remedies, and if any of these were to occur, the possibility exists for a material adverse impact on the Company’s business, results of operations, financial position, and overall trends. The Company might also conclude that settling one or more such matters is in the best interests of its stockholders and its business, and any such settlement could include substantial payments. On August 5, 2010, SciClone was contacted by the SEC and advised that the SEC has initiated a formal, non-public investigation of SciClone, and the SEC issued a subpoena to SciClone requesting a variety of documents and other information including, but not limited to, potential payments or transfers of anything of value to regulators and government-owned entities in China, bids or contracts with state or government-owned entities in China, any joint venture partner, intermediary or local agent of the Company in China, the Company's ethics and anti-corruption policies, training, and audits, and certain company financial and other disclosures. On August 6, 2010, the Company received a letter from the US Department of Justice (“DOJ”) indicating that the DOJ was investigating Foreign Corrupt Practices Act (“FCPA”) issues in the pharmaceutical industry generally, and that the DOJ had information about the Company’s practices suggesting possible violations. The Company received a further subpoena from the SEC in the fourth quarter of fiscal 2012 on additional matters including, but not limited to, matters related to its acquisition of NovaMed and FCPA matters, and certain sales and marketing expenses.
	In response to these matters, the Company’s Board of Directors appointed a Special Committee of independent directors (the “Special Committee”) to oversee the Company’s response to the government inquiry. The Special Committee has undertaken independent investigations as to matters reflected in and arising from the SEC and DOJ investigations in order to evaluate whether any violation of the FCPA or other laws occurred. The Company will continue to cooperate fully with the SEC and DOJ in the conduct of their investigations.
	The Company cannot predict what the outcome of those investigations will be, or the timing of any resolution. However, the Company has determined that a payment of $2.0 million to the government in penalties, fines and/or other remedies is probable. Accordingly, the Company recorded $2.0 million of operating expense in its fourth quarter 2013 results of operations to reflect the Company’s estimate of a probable loss incurred related to potential penalties, fines and/or other remedies in the ongoing investigations with the SEC and DOJ. Any actual fines or penalties that may be imposed, or other losses that may be realized related to the investigations, could materially differ and could be higher from the amount of the Company’s estimated loss and could materially impact the Company’s financial statements. The Company has re-assessed the potential liability in this matter with no significant developments noted in the current quarter, and will continue to reassess the potential liability related to the investigations and adjust its estimates accordingly in future periods.
	NovaMed was a party to a Distribution and Supply Agreement with MEDA Pharma GmbH & Co. KG (“MEDA”). Following the Company’s acquisition of NovaMed, MEDA claimed it had a right to terminate the agreement under a change of control provision. NovaMed does not believe that MEDA had a right of termination under the agreement. As provided in the agreement, disputes, including disputes regarding termination, must be resolved in binding arbitration. NovaMed filed an application for binding arbitration with the China International Economic and Trade Arbitration Commission (“CIETAC”) on July 26, 2012. On April 3, 2014, CIETAC issued the final Award of the Arbitral Tribunal. The Arbitral Tribunal found that MEDA did have a right to terminate the agreement upon a change of control, but that MEDA must make reasonable reimbursement to NovaMed before any products rights are returned to MEDA. The amount that must be paid includes $333,333 as “unjust enrichment” plus an amount for reasonable compensation for such services provided by NovaMed to MEDA. The amount of such payment for services was not determined by the Arbitral Tribunal, but was left to be determined by NovaMed. While NovaMed has the right to make a determination of the reasonable amount of its compensation for services, MEDA may elect to initiate another arbitration if it determines to dispute the reasonableness of NovaMed’s determination. However, NovaMed is not required to return the product rights to MEDA until MEDA either makes payment to NovaMed, or (i) pays $333,333 to NovaMed, (ii) initiates a second CIETAC arbitration and (iii) posts a security bond of $2,666,666. On April 30, 2014, NovaMed informed MEDA that its determination of reasonable compensation for its services was $3,314,629, including the $333,333 for unjust enrichment. As MEDA has not agreed to such amount and could pursue further arbitration, the amount of any final payment to NovaMed remains uncertain, and as such the Company has not recognized it as a gain contingency.
	On March 11, 2013, Adam Crum filed a derivative lawsuit, purportedly in the name of SciClone, against Friedhelm Blobel, Gary Titus, Jon Saxe, Peter Barrett, Richard Hawkins, Gregg Lapointe and Ira Lawrence in California Superior Court, San Mateo County, captioned Crum v. Blobel, et al., Case No. CIV520331. The lawsuit alleges, based on the restatement of the Company’s consolidated financial statements for the year ended December 31, 2011 and certain quarters of 2011 and 2012, that the Board of Directors and management breached their fiduciary duties to the Company by not exercising oversight in such a way that they allowed the Company to file consolidated financial statements that were materially inaccurate. Plaintiff asserts claims for breach of fiduciary duty, abuse of control and mismanagement. Plaintiff seeks, among other things, injunctive relief, disgorgement, undisclosed damages and attorneys’ fees and costs. The Company and other defendants filed motions to dismiss the complaint. The court granted the motions to dismiss but allowed plaintiff to amend the complaint. An amended complaint has not yet been filed. Given the procedural process and the nature of this case, including that a motion to dismiss has been filed, the Company is unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from this matter.
	On or about November 20, 2013, counsel for the Company sent a letter on behalf of the Company’s subsidiary, NovaMed, to Sanofi (Hangzhou) Pharmaceuticals Co. Ltd. and Sanofi (Beijing) Pharmaceuticals Co., Ltd. (collectively, “Sanofi”) (i) asserting that Sanofi had breached its obligations under various agreements (the “Promotion Agreements”) between the parties for the promotion of Depakine®, Stilnox®, Tritace® and Xatral® (collectively the “Products”) by, among other things, failing to supply Products for the fourth quarter of 2013 in relation to sales the Company generated, and failing to pay promotion fees due to NovaMed under the Promotion Agreements, and (ii) demanding that Sanofi make full payment of the promotional fees due to NovaMed, and that Sanofi cause orders to be placed for the Products for November and December of 2013 in specified quantities. NovaMed and Sanofi have discussed potential settlement of the dispute. However, the dispute has not been resolved by the parties. NovaMed has communicated to Sanofi that if the dispute is not resolved to its satisfaction, it intends to exercise all of its legal rights and remedies under the Promotion Agreements, including pursuing arbitration of the dispute through CIETAC pursuant to the terms of the Promotion Agreements. No formal legal proceedings were initiated by or filed against the Company in connection with this matter.
	Purchase Obligations
	Under agreements with certain of the Company’s pharmaceutical partners, the Company is committed to certain annual minimum product purchases where the contract is subject to termination if the annual minimum order is not met. As of March 31, 2014, the Company did not have any material unmet purchase obligations.

Segment_Information_And_Geogra

Segment Information And Geographic Data	3 Months Ended
	Mar. 31, 2014
Segment Information And Geographic Data [Abstract]	'
Segment Information And Geographic Data	'
	9.Segment Information and Geographic Data
	The Company reports segment information based on the internal reporting used by management for evaluating segment performance based on management’s estimates of the appropriate allocation of resources to segments.
	The Company operates and manages its business primarily on a geographic basis. Accordingly, the Company determined its operating and reporting segments, which are generally based on the nature and location of its customers, to be 1) China and 2) Rest of the World, including the US and Hong Kong.
	The Company evaluates the performance of its operating segments based on revenues and operating income (loss). Revenues for geographic segments are generally based on the location of customers. Operating income (loss) for each segment includes revenues, related cost of sales and operating expenses directly attributable to the segment. Operating income (loss) for each segment excludes non-operating income and expense.
	Summary information by operating segment for the three-month periods ended March 31, 2014 and 2013 is as follows (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Revenue:
	China	$	25,679	$	28,810
	Rest of the World (including the US and Hong Kong)		886		996
	Total net revenues	$	26,565	$	29,806
	Income (loss) from operations:
	China	$	7,572	$	10,951
	Rest of the World (including the US and Hong Kong)		-2,911		-5,927
	Total income from operations	$	4,661	$	5,024
	Non-operating income (expense), net:
	China	$	-125	$	-26
	Rest of the World (including the US and Hong Kong)		-4		-8
	Total non-operating expense, net	$	-129	$	-34
	Income (loss) before provision for income tax:
	China	$	7,447	$	10,925
	Rest of the World (including the US and Hong Kong)		-2,915		-5,935
	Total income before provision for income tax	$	4,532	$	4,990
	Long-lived assets as of March 31, 2014 by operating segment are as follows (in thousands):
	China	$	35,397
	Rest of the World (including the US and Hong Kong)		334
		$	35,731

Subsequent_Event

Subsequent Event	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Abstract]	'
Subsequent Event	'
	10.Subsequent Event
	Stock Repurchases: The Company repurchased and retired 464,826 shares at a cost of $2.2 million from April 1, 2014 through May 6, 2014 under its share repurchase program. As of May 6, 2014, $4.9 million of the total $50.5 million was available for future share repurchase.

Basis_Of_Presentation_Policy

Basis Of Presentation (Policy)	3 Months Ended
	Mar. 31, 2014
Basis Of Presentation [Abstract]	'
Basis Of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of SciClone Pharmaceuticals, Inc. (“SciClone” or the “Company”) have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) consistent with those applied in, and should be read in conjunction with, the audited consolidated financial statements and the notes thereto for the year ended December 31, 2013 included in the Company’s Form 10-K as filed with the Securities and Exchange Commission (“SEC”). The Company prepared the unaudited condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other information that are normally required by GAAP can be condensed or omitted.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	The interim financial information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented and are not necessarily indicative of results for subsequent interim periods or for the full year. The unaudited condensed consolidated balance sheet data as of December 31, 2013 is derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.
Use Of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ significantly from those estimates.
Customer Concentration	'
	Customer Concentration
	In China, pharmaceutical products are imported and distributed through a tiered method of distribution. For the Company’s proprietary product ZADAXIN®, the Company manufactures its product using its US and European contract manufacturers, and it generates its product sales revenue through sales of ZADAXIN products to Sinopharm Lingyun Biopharmaceutical (Shanghai) Co. Ltd. (“SinoPharm”). SinoPharm and its affiliates act as an importer, and also as the top “tier” of the distribution system (“Tier 1”) in China. The Company’s ZADAXIN sales occur when the importer purchases product from the Company, without any right of return except for damaged product or quality control issues and after passage of title and risk of loss are transferred to SinoPharm at the time of shipment. After the Company’s sale, SinoPharm clears products through China import customs, sells directly to large hospitals and holds additional product it has purchased in inventory for sale to the next tier in the distribution system. The second-tier distributors are responsible for the further sale and distribution of the products they purchase from the importer, either through sales of product directly to the retail level (hospitals and pharmacies), or to third-tier local or regional distributors who, in turn, sell products to hospitals and pharmacies. The Company’s other product sales revenues result from the sale of the Company’s in-licensed products to importing agents and distributors.
	Promotion services revenues result from fees received for exclusively promoting products for certain pharmaceutical partners. These importing agents, distributors and partners are the Company’s customers.
	Customers that exceeded 10% of the Company’s total net revenue and related to the Company’s China segment were as follows:
		Three Months Ended
		March 31,
		2014		2013
	Customer A		94%		66%
	Customer B		—		29%
	As of March 31, 2014, approximately $31.2 million, or 87%, of the Company's accounts receivable were attributable to two customers in China. The Company generally does not require collateral from its customers.
Accounts Receivable	'
	Accounts Receivable
	Receivable Reserve. The Company records a receivable reserve based on a specific review of its overdue invoices. The Company’s estimate for a reserve is determined after considering its existing contractual payment terms, payment patterns of its customers and individual customer circumstances, the age of any outstanding receivables and its current customer relationships. Accounts receivable are charged off at the point when they are considered uncollectible. As of March 31, 2014, the Company had $7.6 million in accounts receivable that were past due ninety days or more. As of March 31, 2014 and December 31, 2013, the Company recorded a receivable reserve of approximately $3.5 million related to gross accounts receivable of $3.5 million from one customer that is more than one year past due. The accounts receivable reserve was established as a result of continual negotiations that indicate the accounts receivable balance may not be recoverable. The receivable reserve reflects the Company’s best estimate of the ultimate collection, though actual collections may vary and the Company continues to pursue the full amount of the accounts receivables. The Company also had an additional receivable reserve of $0.1 million as of March 31, 2014 and December 31, 2013 related to another customer due to the Company’s uncertainty of collecting a portion of the outstanding accounts receivable balance. The remaining amount past due ninety days or more related to receivables from affiliates of Sanofi Aventis S. A. (“Sanofi”) and had not been reserved for as of March 31, 2014 due to (i) the progress towards resolving the current dispute and (ii) the fact that a substantial portion of the total receivables due from Sanofi were offset by unrecognized revenue that had been deferred in the fourth quarter of 2013. Refer to further information regarding this matter under “Revenue Recognition” “Promotion Services Revenue.”
	Revenue Reserve. The Company maintains a revenue reserve for product returns based on estimates of the amount of product to be returned by its customers which may result from expired or damaged product on delivery or for price reductions on the related sales and is based on historical patterns, analysis of market demand and/or a percentage of sales based on industry trends, and management’s evaluation of specific factors that may increase the risk of product returns. Importing agents or distributors do not have contractual rights of return except under limited terms regarding product quality. However, the Company is expected to replace products that have expired on delivery or are deemed to be damaged or defective when delivered. The calculation of the revenue reserve requires estimates and involves a high degree of subjectivity and judgment. As a result of the uncertainties involved in estimating the revenue reserve, there is a possibility that materially different amounts could be reported under different conditions or using different assumptions. As of March 31, 2014 and December 31, 2013, the Company’s revenue reserves were immaterial.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue when persuasive evidence of an arrangement exists, services have been rendered or delivery has occurred, the price to the buyer is fixed or determinable and collectability is reasonably assured.
	Product Revenue. The Company recognizes product revenue from selling manufactured ZADAXIN product at the time of delivery. Sales of ZADAXIN to SinoPharm and its affiliates are recognized at time of shipment when title to the product is transferred to them. The Company also earns product revenue from purchasing medical products from pharmaceutical companies and selling them directly to importers or distributors. The Company recognizes revenue related to these products based on the “sell-in” method, when the medical products have been delivered to the importers or distributors. Payments by the importing agents and distributors are not contingent upon sale to the end user by the importing agents or distributors.
	Promotion Services Revenue. The Company recognizes promotion services revenue after designated medical products are delivered to the distributors as specified in the promotion services contract, which marks the period when marketing and promotion services have been rendered and the revenue recognition criteria are met. In certain arrangements, the Company is required to return or refund a portion of promotion services fees received during interim periods from pharmaceutical customers if defined annual sales targets are not achieved. Under the Company’s agreements with these customers, if the agreement is terminated, and provided such targets have been met on a “pro rata” basis at the date of contract termination, the Company is entitled to retain the amounts paid. Due to the ability to retain amounts paid upon contract termination, provided applicable targets have been met on a “pro rata” basis at any interim date, the Company elected to recognize revenue during interim periods without reduction for amounts subject to refund based on Method 2 of Accounting Standards Codification 605-20-S99-1, “Accounting for Management Fees Based on a Formula.”
	The Company’s promotion agreements with Sanofi, consisting of individual promotional agreements for certain pharmaceutical products and supplementary agreements extending the terms thereof, were not renewed and expired on December 31, 2013. The Company received initial notification of non-renewal from Sanofi in early October 2013. Subsequent thereto, the Company believes that Sanofi breached its obligations under these agreements by, among other things, failing to supply product for the fourth quarter of 2013 in relation to sales the Company generated, and failing to pay promotion fees due to NovaMed Pharmaceuticals (Shanghai) Co. Ltd. (“NovaMed”) under the agreements. As of March 31, 2014 and December 31, 2013, the Company had $3.3 million and $4.3 million, respectively, of uncollected receivables due from Sanofi that related to revenue recognized during the first three quarters of 2013. The Company has demanded that Sanofi make full payment of the promotional fees due to NovaMed. If this matter is not resolved to the Company’s satisfaction, the Company intends to vigorously pursue its claims against Sanofi in arbitration. The Company is also pursuing settlement options outside of formal arbitration.
	The Company’s agreements with Sanofi contain provisions (identical regardless of individual product promotion agreement) that required a refund of a portion of promotion services fees received during interim periods from them if defined annual sales targets were not achieved. Consistent with the Company’s past practice, and consistent with its achievement (or excess achievement) of annual revenue targets in each prior period based on Method 2 of Accounting Standards Codification 605-20-S99-1, “Accounting for Management Fees Based on a Formula,” the Company recognized revenue during interim periods without reduction for amounts subject to refund because it met and substantially exceeded such targets on a “pro rata” basis at interim dates. The Company’s treatment of the subject-to-refund portion is consistent with the contractual provisions, which provide that the sales targets will be measured on a pro-rated basis if an agreement were to hypothetically terminate as of any given date.
	Due to Sanofi’s failure to place orders for shipment in the fourth quarter and fully meet the demand the Company generated, the Company’s actual promotional fees receivable in the fourth quarter of 2013 were negatively impacted. Due to this failure, the Company did not achieve the defined annual sales targets for fiscal 2013. Under the Company’s agreements with Sanofi, a failure to reach the annual sales target would result in approximately $6.2 million subject to refund related to the Company’s performance in the first three quarters of 2013. However, the Company’s agreements required that Sanofi continue to support the Company’s sales efforts by continuing to provide product through the end of the terms of the agreements. The Company believes it has no obligation to refund any amounts subject to this provision because its inability to achieve the defined annual sales was the result of a failure to perform by Sanofi.
	As the Company is in a dispute with Sanofi concerning Sanofi’s performance, the Company therefore deferred revenue recognition of approximately $2.8 million of Sanofi promotion fees related to the fourth quarter of 2013, pending resolution of the dispute. As the Company is legally entitled to at least the $2.8 million recorded as a receivable, the non-recognition of revenue resulted in an equal and offsetting amount of deferred revenue.
Inventories	'
	Inventories
	Inventories consist of raw materials, work in progress and finished goods products. Inventories are valued at the lower of cost or market (net realizable value), with cost determined on a first-in, first-out basis, and include amounts related to materials, labor and overhead. The Company periodically reviews the inventory in order to identify excess and obsolete items, including pharmaceutical products approaching their expiry dates. If obsolete or excess items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the impairment is first recognized. For the three-month period ended March 31, 2014, the Company did not record any write-downs related to inventory.
Net Income Per Share	'
	Net Income Per Share
	Basic net income per share has been computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted net income per share is computed by dividing net income by the weighted-average number of common equivalent shares outstanding for the period. Diluted net income per share includes any dilutive impact from outstanding stock options, restricted stock units (“RSUs”) and the employee stock purchase plan using the treasury stock method.
	The following is a reconciliation of the numerator and denominators of the basic and diluted net income per share computations (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2014			2013
	Numerator:
	Net income	$	4,134		$	4,203
	Denominator:
	Weighted-average shares outstanding used to
	compute basic net income per share		52,026			54,084
	Effect of dilutive securities		1,208			1,388
	Weighted-average shares outstanding used to
	compute diluted net income per share		53,234			55,472
	Basic net income per share	$	0.08		$	0.08
	Diluted net income per share	$	0.08		$	0.08
	For the three months ended March 31, 2014 and 2013, outstanding stock options and RSUs for 3,592,835 and 2,856,805 shares, respectively, were excluded from the calculation of diluted net income per share because the effect from the assumed exercise of these options and RSUs calculated under the treasury stock method would have been anti-dilutive. In addition, for the three months ended March 31, 2014 and 2013, shares subject to market or performance conditions of 62,500 and 12,500, respectively, were excluded from the calculation of diluted net income per share because the performance or market criteria had not been met and the inclusion would provide an anti-dilutive effect.

Basis_Of_Presentation_Tables

Basis Of Presentation (Tables)	3 Months Ended
	Mar. 31, 2014
Basis Of Presentation [Abstract]	'
Schedule Of Revenue By Major Customers By Reporting Segments	'
		Three Months Ended
		March 31,
		2014		2013
	Customer A		94%		66%
	Customer B		—		29%
Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income Per Share Computations	'
		Three Months Ended
		March 31,
		2014			2013
	Numerator:
	Net income	$	4,134		$	4,203
	Denominator:
	Weighted-average shares outstanding used to
	compute basic net income per share		52,026			54,084
	Effect of dilutive securities		1,208			1,388
	Weighted-average shares outstanding used to
	compute diluted net income per share		53,234			55,472
	Basic net income per share	$	0.08		$	0.08
	Diluted net income per share	$	0.08		$	0.08

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Financial Assets And Liability Measured At Fair Value On A Recurring Basis	'
		Fair Value Measurements as of March 31, 2014 Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for		Observable		Unobservable		Balance
			Identical Assets		Inputs		Inputs		as of
	Description		(Level 1)		(Level 2)		(Level 3)		31-Mar-14
	Certificate of deposit	$	—	$	75	$	—	$	75
	Money market funds		19,678		—		—		19,678
	Total	$	19,678	$	75	$	—	$	19,753
		Fair Value Measurements as of December 31, 2013 Using
			Quoted Prices in		Significant
			Active Markets		Other		Significant
			for		Observable		Unobservable		Balance
			Identical Assets		Inputs		Inputs		as of
	Description		(Level 1)		(Level 2)		(Level 3)		31-Dec-13
	Certificate of deposit	$	—	$	75	$	—	$	75
	Money market funds		28,262		—		—		28,262
	Total	$	28,262	$	75	$	—	$	28,337

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Schedule Of Inventories	'
		March 31,		December 31,
		2014		2013
	Raw materials	$	7,763	$	7,746
	Work in progress		363		319
	Finished goods		5,923		7,173
		$	14,049	$	15,238

Accrued_And_Other_Current_Liab1

Accrued And Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued And Other Current Liabilities [Abstract]	'
Schedule Of Accrued And Other Current Liabilities	'
		March 31,		December 31,
		2014		2013
	Accrued taxes, tax reserves and interest	$	4,879	$	5,029
	Accrued sales and marketing expenses		4,210		6,419
	Accrued estimated SEC and DOJ investigation loss (Note 8)		2,000		2,000
	Accrued compensation and benefits		1,597		3,475
	Accrued professional fees		1,335		1,601
	Accrued manufacturing costs		915		1,617
	Other		896		1,323
		$	15,832	$	21,464

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Schedule Of Changes In The Composition Of Accumulated Other Comprehensive Income (Loss)	'
		Foreign
		Currency		Available-for-Sale
		Translation		Investments		Total
	Balances as of January 1, 2014	$	4,176	$	—	$	4,176
	Other comprehensive loss		-859		—		-859
	Balances as of March 31, 2014	$	3,317	$	—	$	3,317
		Foreign
		Currency		Available-for-Sale
		Translation		Investments		Total
	Balances as of January 1, 2013	$	3,055	$	-67	$	2,988
	Other comprehensive income (loss)		178		-10		168
	Balances as of March 31, 2013	$	3,233	$	-77	$	3,156

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity [Abstract]	'
Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Operations	'
		Three Months Ended
		March 31,
			2014		2013
	Sales and marketing	$	201	$	246
	Research and development		47		9
	General and administrative		634		764
		$	882	$	1,019

Segment_Information_And_Geogra1

Segment Information And Geographic Data (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Information And Geographic Data [Abstract]	'
Summary Information By Operating Segment	'
		Three Months Ended
		March 31,
		2014		2013
	Revenue:
	China	$	25,679	$	28,810
	Rest of the World (including the US and Hong Kong)		886		996
	Total net revenues	$	26,565	$	29,806
	Income (loss) from operations:
	China	$	7,572	$	10,951
	Rest of the World (including the US and Hong Kong)		-2,911		-5,927
	Total income from operations	$	4,661	$	5,024
	Non-operating income (expense), net:
	China	$	-125	$	-26
	Rest of the World (including the US and Hong Kong)		-4		-8
	Total non-operating expense, net	$	-129	$	-34
	Income (loss) before provision for income tax:
	China	$	7,447	$	10,925
	Rest of the World (including the US and Hong Kong)		-2,915		-5,935
	Total income before provision for income tax	$	4,532	$	4,990
Long-Lived Assets By Operating Segment	'
	China	$	35,397
	Rest of the World (including the US and Hong Kong)		334
		$	35,731

Basis_Of_Presentation_Narrativ

Basis Of Presentation (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Basis of Presentation [Line Items]	'	'	'
Customer revenue percentage	10.00%	'	'
Accounts receivable past due ninety days or more	$7,600,000	'	'
Allowance for doubtful accounts	3,592,000	'	3,587,000
Additional receivable reserve	100,000	'	100,000
Revenues	26,565,000	29,806,000	'
One Customer [Member]	'	'	'
Basis of Presentation [Line Items]	'	'	'
Accounts receivable gross	3,500,000	'	3,500,000
Allowance for doubtful accounts	3,500,000	'	3,500,000
Number of customers	1	'	1
Period past due	'1 year	'	'1 year
Accounts Receivable Attributable to Two Customers [Member]	'	'	'
Basis of Presentation [Line Items]	'	'	'
Accounts receivable gross	31,200,000	'	'
Percentage of accounts receivable, gross	87.00%	'	'
Number of customers	2	'	'
Sanofi [Member]	'	'	'
Basis of Presentation [Line Items]	'	'	'
Uncollected receivables	3,300,000	'	4,300,000
Revenues subject to refund	6,200,000	'	'
Deferred revenue	2,800,000	'	'
Accounts receivable	$2,800,000	'	'
Stock Options And RSUs [Member]	'	'	'
Basis of Presentation [Line Items]	'	'	'
Shares excluded from the calculation of diluted net income per share	3,592,835	2,856,805	'
Performance-Based Stock Options [Member]	'	'	'
Basis of Presentation [Line Items]	'	'	'
Shares excluded from the calculation of diluted net income per share	62,500	12,500	'

Basis_Of_Presentation_Schedule

Basis Of Presentation (Schedule Of Revenue By Major Customers By Reporting Segments) (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Customer A [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Percentage of sales to importing or distributor agents	94.00%	66.00%
Customer B [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Percentage of sales to importing or distributor agents	'	29.00%

Basis_Of_Presentation_Reconcil

Basis Of Presentation (Reconciliation Of The Numerator And Denominators Of The Basic And Diluted Net Income Per Share Computations) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basis Of Presentation [Abstract]	'	'
Net income	$4,134	$4,203
Weighted-average shares outstanding used to compute basic net income per share	52,026	54,084
Effect of dilutive securities	1,208	1,388
Weighted-average shares outstanding used to compute diluted net income per share	53,234	55,472
Basic net income per share	$0.08	$0.08
Diluted net income per share	$0.08	$0.08

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	$19,753	$28,337
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	19,678	28,262
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	75	75
Certificates of Deposit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	75	75
Certificates of Deposit [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	75	75
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	19,678	28,262
Money Market Funds [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value	$19,678	$28,262

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Raw materials	$7,763,000	$7,746,000
Work in progress	363,000	319,000
Finished goods	5,923,000	7,173,000
Inventory, net	14,049,000	15,238,000
Inventory held at distributors	$1,600,000	$2,400,000

Credit_Facilities_Details

Credit Facilities (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
	Shanghai Pudong Development Bank Co. Ltd. [Member]	Shanghai Pudong Development Bank Co. Ltd. [Member]	Shanghai Pudong Development Bank Co. Ltd. [Member]	NovaMed [Member]	NovaMed [Member]	NovaMed [Member]	NovaMed [Member]	NovaMed [Member]	NovaMed [Member]	NovaMed [Member]
	USD ($)	CNY	USD ($)	USD ($)	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Secured Debt [Member]	Secured Debt [Member]
					USD ($)	CNY	USD ($)	CNY	USD ($)	CNY
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'	'	'	'
Debt financing facility, maximum borrowing capacity	$2,000,000	12,500,000	'	'	'	'	$1,600,000	10,000,000	$2,400,000	15,000,000
Debt financing facility, amount borrowed	'	'	'	'	1,600,000	10,000,000	'	'	'	'
Percentage points added to reference rate	'	'	'	15.00%	'	'	'	'	'	'
Effective interest rate	'	'	7.50%	6.44%	'	'	'	'	'	'
Debt financing facility, expiration date	29-Aug-13	29-Aug-13	'	30-Nov-14	'	'	'	'	'	'
Interest paid	'	'	$31,000	$26,000	'	'	'	'	'	'

Accrued_And_Other_Current_Liab2

Accrued And Other Current Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued And Other Current Liabilities [Abstract]	'	'
Accrued taxes, tax reserves and interest	$4,879	$5,029
Accrued sales and marketing expenses	4,210	6,419
Accrued estimated SEC and DOJ investigation loss (Note 8)	2,000	2,000
Accrued compensation and benefits	1,597	3,475
Accrued professional fees	1,335	1,601
Accrued manufacturing costs	915	1,617
Other	896	1,323
Accrued and other current liabilities, total	$15,832	$21,464

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Schedule Of Changes In The Composition Of Accumulated Other Comprehensive Income (Loss)) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]	'	'
Foreign Currency Translation, Beginning balance	$4,176	$3,055
Foreign Currency Translation, Other comprehensive income (loss)	-859	178
Foreign Currency Translation, Ending balance	3,317	3,233
Available-for-Sale Investments, Beginning balance	'	-67
Available-for-Sale Investments, Other comprehensive (loss)	'	-10
Available-for-Sale Investments, Ending balance	'	-77
Beginning balance	4,176	2,988
Other comprehensive income (loss)	-859	168
Ending balance	$3,317	$3,156

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expenses recognized	$882,000	$1,019,000
Share repurchase program, amount authorized	50,500,000	'
Stock repurchased and retired, shares	500,003	'
Stock repurchased and retired, value	2,600,000	'
Share repurchase program, remaining amount authorized	7,100,000	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Common stock, options granted, shares	1,434,500	'
Common stock, option exercises, shares	80,622	'
Unrecognized compensation expense, net of forfeitures	5,700,000	'
Unrecognized compensation expense, weighted-average remaining period for recognition, in years	'3 years 1 month 10 days	'
Performance-Based Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation expenses recognized	24,000	0
Common stock, options granted, shares	100,000	'
Number of performance-based options	2	'
Stock-based compensation, option term	'10 years	'
Fair value assumption, method used to calculate grant date fair value per share	'Black-Scholes option pricing model	'
RSUs [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Unrecognized compensation expense, net of forfeitures	$600,000	'
Unrecognized compensation expense, weighted-average remaining period for recognition, in years	'1 year 2 months 1 day	'
RSUs granted, shares	7,000	'
RSUs vested, shares	625	'
Minimum [Member] | Performance-Based Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	0.95%	'
Volatility factor of the market price of common stock	61.74%	'
Fair value assumption, expected term, in years	'4 years 11 months 12 days	'
Maximum [Member] | Performance-Based Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate	1.49%	'
Volatility factor of the market price of common stock	64.65%	'
Fair value assumption, expected term, in years	'5 years 11 months 19 days	'

Stockholders_Equity_StockBased

Stockholders' Equity (Stock-Based Compensation Expenses Included In The Condensed Consolidated Statements Of Operations) (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expenses recognized	$882,000	$1,019,000
Sales And Marketing [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expenses recognized	201,000	246,000
Research And Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expenses recognized	47,000	9,000
General And Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expenses recognized	$634,000	$764,000

Contingencies_And_Commitments_

Contingencies And Commitments (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Apr. 30, 2014	Apr. 03, 2014
			NovaMed [Member]	NovaMed [Member]
Probable payment to government in penalties, fines and/or other remedies	$2,000,000	'	'	'
Estimated SEC/DOJ investigation loss	'	2,000,000	'	'
Reimbursement for unjust enrichment	'	'	'	333,333
Security bond for compensation of services provided	'	'	'	2,666,666
Determination of reasonable compensation for services provided, including unjust enrichment	'	'	$3,314,629	'

Segment_Information_And_Geogra2

Segment Information And Geographic Data (Summary Information By Operating Segment) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenue	$26,565	$29,806
Income (loss) from operations	4,661	5,024
Non-operating income (expense), net	-129	-34
Income (loss) before provision for income tax	4,532	4,990
China [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	25,679	28,810
Income (loss) from operations	7,572	10,951
Non-operating income (expense), net	-125	-26
Income (loss) before provision for income tax	7,447	10,925
Rest Of The World (Including The U.S.) [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenue	886	996
Income (loss) from operations	-2,911	-5,927
Non-operating income (expense), net	-4	-8
Income (loss) before provision for income tax	($2,915)	($5,935)

Segment_Information_And_Geogra3

Segment Information And Geographic Data (Long-Lived Assets By Operating Segment) (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Segment Reporting Information [Line Items]	'
Long-lived assets	$35,731
China [Member]	'
Segment Reporting Information [Line Items]	'
Long-lived assets	35,397
Rest Of The World (Including The U.S.) [Member]	'
Segment Reporting Information [Line Items]	'
Long-lived assets	$334

Subsequent_Event_Details

Subsequent Event (Details) (USD $)	3 Months Ended	1 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	6-May-14
		Subsequent Event [Member]
Subsequent Event [Line Items]	'	'
Stock repurchased and retired, shares	500,003	464,826
Stock repurchased and retired, value	$2.60	$2.20
Share repurchase program, remaining amount authorized	7.1	4.9
Share repurchase program, amount authorized	$50.50	'